Reconstruction of Urethral Sphincter With Polyacrylamide Hydrogel.
| Autor: | Clearwater WL, Panushka K; Urology, Albert Einstein College of Medicine, Montefiore Hospital., Najor A; Urology, Albert Einstein College of Medicine, Montefiore Hospital., Laudano M, Fleischmann N; Department of Urology, White Plains Hospital, White Plains, NY. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Urogynecology (Philadelphia, Pa.) [Urogynecology (Phila)] 2024 Mar 01; Vol. 30 (3), pp. 293-299. Date of Electronic Publication: 2024 Mar 06. |
| DOI: | 10.1097/SPV.0000000000001470 |
| Abstrakt: | Importance: Urethral bulking is an alternative to synthetic midurethral sling for the treatment of stress urinary incontinence (SUI) in women. Urethral bulking agents, which are injected in the submucosal tissues of the proximal urethra/bladder neck, have demonstrated less adverse effects with similar satisfaction rates but lower subjective and objective cure rates when compared with midurethral sling. Cystoscopic Reconstruction of External Sphincter Technique (CREST) is a novel technique, which reinforces the natural closure mechanism of the external urinary sphincter (EUS). Objective: The aim of the study was to provide safety and efficacy data for injecting polyacrylamide hydrogel (PAHG) in the components of the female EUS. Study Design: This was a retrospective chart review of patients using CREST with PAHG as initial treatment for SUI by a single surgeon from January 2022 to October 2022. Exclusion criteria are as follows: younger than 18 years, prior SUI surgery, concomitant pelvic organ prolapse or reconstructive procedure, neurological conditions, or history of radiation. Subjective and objective cure rates were measured by patient-reported symptoms and cough stress test. Urinary retention, postoperative urinary infection, and de novo urinary urgency were assessed. Results: One hundred and thirteen consecutive patients met inclusion criteria with median follow-up of 3 months. Eighty-five percent of participants reported subjective improvement, 69% reported subjective cure, and 69% demonstrated objective cure. Nine patients reported transient postoperative retention, 8 reported postoperative urinary tract infections, and 5 reported de novo urgency. There were no serious adverse events. Conclusions: CREST is a novel technique for injection of PAHG, into the EUS to treat SUI. Our data suggest that this technique could improve urethral injection outcomes with minimal complications. Competing Interests: The authors have declared they have no conflicts of interest. (Copyright © 2024 American Urogynecologic Society. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|